Group 16-20

clinical stage biopharmaceutical company developing oral covalent small molecule inhibitors to treat cancers and metabolic diseases

built their own fusion system platform ro develop treatments against high value oncogenic drivers

revenue stage, fully integrated biopharma

biosimilar development and immuno-oncology therapeutics

clinical stage immuno oncology

next gen cd47 blocking therapeutics

clinical stage biotech company

usage of combination therapies focusing on the enhancement of the immune system to treat various infectious and oncological diseases

service based biotech company that will partner with pharmaceutical companies to generate thepapeutics

Transgenic animal technology to produce human antibodies * OmniRat, Omnimouse, OmniChicken, OmniTaur, OmniClic, OmniFlic, OmnidAb

clinical stage biotech committed to discovering novel drug targets and developing next gen of precision meds for the treatment of cancer

synthetic lethality for targeting specific tumor suppressor gene loss

clinical stage drug delivery platform biopharmaceutical company

enhanze drug delivery tech for subcutaneous administration of injected drugs

single domain antibody (sdAb) platform foundation to build novel drugs that target a variety of cancers (chondrosarcomas, nonsmall cell lung cancer, head/neck cancer) and alpha 1 antitrypsin (AAT) deficiency, which affects the lungs

core sdAb platform is composed of camelid-derived heavy-chain-only antibodies that are miniaturized into sdAbs

precision medecine focused, clinical stage biotech focusing on targeted therapied for cancer treatment

Synthetic Lethality (SL), as shown in the figure above, is a drug development strategy that targets specific genetic interactions between two genes to selectively kill cancer cells by exploiting vulnerabilities created by the loss or mutation of certain genes that occurred exclusively in cancer cells.

integration of early-stage research platforms, gene therapy, RNA End-Joining, protein deimmunization, synthetic rescue and proprietary manufacturing.

leading gastrointestical focused biopharmaceutical company

clinical stage global biopharma specializing in orally available small molecules targeting G-Coupled Protein Receptors (GPCR

drug discovery and development kinase inhibitor company

Kinase inhibition via cystine residues using analysis technology, KINect

clinical stage gene therapy company